ISRCTN81306618已完成不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of dihydroartemisinin and piperaquine (DHA + PPQ, Artekin®) in comparison with artesunate and mefloquine (AS + MQ) in patients affected by acute, uncomplicated Plasmodium falciparum malaria
Sigma-Tau (Italy)0 个研究点目标入组 1,050 人开始时间: 2005年5月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Males and females aged between three months and 65 years inclusive
- •2. Body weight at least 5 kg
- •3. Microscopically confirmed, monoinfection of Plasmodium falciparum or mixed infection
- •4. History of fever or presence of fever (tympanic temperature at more than or equal to 37.5°C)
- •5. Written informed consent
- •6. 1050 patients (700 DHA + PPQ; 350 AS + MQ)
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of Dihydroartemisinin and Piperaquine (DHA + PPQ, Artekin®) in comparison with Artemether and Lumefantrine (A + L, Coartem®) in children with uncomplicated Plasmodium falciparum malariaInfections and InfestationsPlasmodium falciparum malariaMalariaISRCTN16263443Sigma-Tau (Italy)1,500
已完成
3 期
SPIRIT 3: To evaluate the most effective way to use imatinib, nilotinib and ponatinib in the treatment of chronic myeloid leukaemiaChronic myeloid leukaemiaChronic myeloid leukaemia [CML], BCR/ABL-positiveCancerISRCTN60655195ewcastle-upon-Tyne Hospitals NHS Foundation Trust (UK)1,000
进行中（未招募）
1 期
SPIRIT 3 - a phase 3 randomised trial to evaluate the most effective way to use drug treatments in newly diagnosed early stage chronic myeloid leukaemia (cancer of blood which starts in bone marrow) patientsEUCTR2012-005696-14-GBewcastle upon Tyne Hospitals NHS Foundation Trust1,000
招募中
1 期
Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenouslyewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000996-38-ATRuprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg514
招募中
1 期
Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenouslyewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000996-38-DERuprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg514